8Carey RM ,Wang ZQ,Siragy HM,et al. Role of angiotensin Ⅱ type 2 receptor in the regulation of blood pressure and renal function[ J].Hypertension,2000,35 ( 1 Pt 2) :155-163.
9Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting--enzyme inhibitor in normotensive and hypertensive subjects [ J ]. N Engt J Med,1998,339( 18 ) : 1285-1292.
10Fauvel JP,Velon S, Berra N,et al. Effects of losaxtan on renal function in patients with essential hypertention[ J]. J Cardiovasc Pharmacol,1996,28(2) :259-263.
5Lehmann R, Schleicher ED .Molecular mechanism of diabetic nephropathy. Clin Chim Acta,2000, 297(1-2):135
6Ceriello A, Quatraro A, Giugliano D. New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med,1992, 9(3):297
7Tall MW,Brenner BM.Renalprotective benefits of RAS inhibition:from ACEI to agniotensin Ⅱ antagonists.Kidney Int,2000,57:1803
8Tarif N,Bakris GL,Angiotensin Ⅱ receptor blockade and progression of nondiabetic-mediated renal disease.Kidney Int,1997,52(Suppl 63):67s
9Gasparo MDE,Levens NR.Pharmacology of angiotensin Ⅱ receptor in the kidney.Kidney Int,1994,46:1486
10Loutzenhiser R,Epstein M,Hayashi K,et al.Characterization of the renal microvascular effects of angiotensin Ⅱ antagonist,DuP753:studies in isolated perfused hydronephrotic kidney.Am J Hypertens,1991,4(4):309s
3National Kidney Foundation Kidney.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification and stratification[].American Journal of Kidney Diseases.2002
4Chobanian AV,Bakris GL,Black HR,et al.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[].Journal of the American Medical Association The.2003
5Mann Johannes F E,Schmieder Roland E,McQueen Matthew,Dyal Leanne,Schumacher Helmut,Pogue Janice,Wang Xingyu,Maggioni Aldo,Budaj Andrzej,Chaithiraphan Suphachai,Dickstein Kenneth,Keltai Matyas,Mets?rinne Kaj,Oto Ali,Parkhomenko Alexander,Pie.Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial[].The Lancet.2008
6Coresh Josef,Selvin Elizabeth,Stevens Lesley A,Manzi Jane,Kusek John W,Eggers Paul,Van Lente Frederick,Levey Andrew S.Prevalence of chronic kidney disease in the United States[].JAMA : the journal of the American Medical Association.2007
7Hallan Stein I,Coresh Josef,Astor Brad C,Asberg Arne,Powe Neil R,Romundstad Solfrid,Hallan Hans A,Lydersen Stian,Holmen Jostein.International comparison of the relationship of chronic kidney disease prevalence and ESRD risk[].Journal of the American Society of Nephrology : JASN.2006
8Peterson J C,Adler S,Burkart J M,et al.Blood pressure control, proteinuria, and the progression of renal disease.The Modification of Diet in Renal Disease Study[].Annals of Internal Medicine.1995
9Fan Fan Hou,Di Xie,Xun Zhang,Ping Yan Chen,Wei Ru Zhang,Min Liang,Zhi Jian Guo,Jian Ping Jiang.Clinical Science Articles - Clinical Nephrology - Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency[].Journal of the American Society of Nephrology : JASN.2007
